Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895

Futu News05:31 · Ratings

Express News | Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at Ash

BreakingsNov 13 20:00

Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight

PR NewswireNov 13 06:31

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

Simply Wall StNov 12 21:35

Regeneron Announces Investor Conference Presentations

GlobeNewswireNov 12 05:05

Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,175

MT NewswiresNov 11 20:57 · Ratings